Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000681)

(Analysis AN001048)

Metabolite	Structure	F1	F2	F3	F4	F5
PC 33:2; [M-Ac-H]-@5.88	ME189531	0.93	1.14	0.98	1.82	0.73
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.77	ME189522	1.69	0.75	0.90	0.50	0.66
PS 38:5; [M-H]-@5.52	ME189604	0.92	0.77	1.15	0.74	1.16
PE 35:4; [M-H]-@6.00	ME189561	1.09	0.89	1.19	0.21	0.94
PE 37:4; [M-H]-@6.63	ME189565	1.16	0.84	1.08	0.56	0.97
PG 33:0; [M-H]-@6.04	ME189577	1.16	0.98	0.93	0.40	1.12
PS 42:9; [M-H]-@5.07	ME189614	1.13	1.31	0.83	0.70	0.89
CL 72:5; [M-2H](2-)@9.44	ME189504	0.96	1.57	0.96	0.73	0.63
PS 40:8; [M-H]-@4.86	ME189609	0.84	1.31	1.18	0.73	0.70
PG 42:9; [M-H]-@4.87	ME189591	0.77	1.57	0.80	1.04	1.05
PE 40:9; [M-H]-@5.52	ME189569	0.87	1.25	0.89	1.26	1.02
PS 44:11; [M-H]-@4.92	ME189616	0.87	1.17	0.94	1.17	1.06
PG 44:10; [M-H]-@5.10	ME189592	0.85	1.19	1.05	0.92	0.96
PE 42:6; [M-H]-@7.40	ME189572	0.82	1.26	0.93	1.06	1.07
PS 44:10; [M-H]-@5.31	ME189615	0.94	1.23	0.94	1.02	0.95
FFA(24:3)	ME189521	1.37	0.96	0.79	1.21	0.83
PC 32:2; [M-Ac-H]-@5.53	ME189529	1.24	0.95	0.79	1.31	0.96
PC 42:6; [M-Ac-H]-@7.30	ME189556	1.19	1.08	0.82	1.30	0.87
FFA(24:0)	ME189519	1.01	1.37	0.93	1.25	0.65
PG 34:2; [M-H]-@5.43	ME189579	0.97	1.25	0.96	1.13	0.81
PC 34:3; [M-Ac-H]-@5.66	ME189534	1.06	1.14	1.03	1.26	0.63
FFA(22:2)	ME189517	1.16	1.09	0.99	1.05	0.69
PE 35:0; [M-H]-@7.50	ME189560	1.12	1.00	1.01	1.18	0.77
PS 42:10; [M-H]-@4.80	ME189610	1.22	0.96	0.97	1.20	0.73
FFA(20:2)	ME189513	1.38	0.85	0.93	0.79	0.83
FFA(18:1)	ME189509	1.27	0.89	1.00	0.86	0.78
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.37	ME189523	1.29	0.83	0.99	0.82	0.86
FFA(18:2)	ME189510	1.44	0.98	0.86	0.75	0.75
FFA(22:3)	ME189518	1.35	0.98	0.92	0.93	0.71
PG 36:3; [M-H]-@5.61	ME189581	1.03	1.07	0.99	0.91	0.94
plasmenyl-PE 38:2; [M-H]-@7.79	ME189624	0.97	1.11	1.03	0.93	0.91
PS 42:7; [M-H]-@5.99	ME189613	1.03	1.04	1.07	0.99	0.81
PC 38:6; [M-Ac-H]-@5.97	ME189550	0.97	1.07	1.05	0.99	0.87
PG 36:4; [M-H]-@5.42	ME189582	1.04	1.08	1.01	1.01	0.86
PS 40:7; [M-H]-@5.37	ME189608	1.03	1.08	1.06	0.84	0.83
PS 34:2; [M-H]-@5.30	ME189599	0.99	1.18	1.00	0.96	0.85
PC 40:4; [M-Ac-H]-@7.22	ME189553	1.06	1.18	0.98	0.90	0.79
PI 38:4; [M-H]-@5.87	ME189597	1.02	1.16	1.04	0.93	0.77
PI 36:4; [M-H]-@5.21	ME189596	1.08	1.25	0.90	0.92	0.83
CL 72:4; [M-2H](2-)@9.62	ME189503	1.11	1.16	0.97	0.79	0.81
PC 37:4; [M-Ac-H]-@6.44	ME189543	1.14	1.10	1.00	0.88	0.75
CL 76:11; [M-2H](2-)@9.02	ME189506	1.10	1.11	0.96	0.71	0.93
PG 40:8; [M-H]-@4.65	ME189589	1.10	1.12	0.91	0.81	0.96
CL 74:7; [M-2H](2-)@9.52	ME189505	1.27	0.98	1.00	0.61	0.78
PG 32:0; [M-H]-@5.77	ME189576	1.17	1.02	0.98	0.70	0.88
PG 40:7; [M-H]-@5.18	ME189588	1.16	1.01	1.03	0.75	0.79
PS 44:12; [M-H]-@4.69	ME189617	0.85	1.00	1.02	1.23	1.09
plasmenyl-PE 32:0; [M-H]-@7.01	ME189618	0.97	1.09	1.01	1.12	0.91
PS 42:11; [M-H]-@4.38	ME189611	0.94	1.05	1.07	1.13	0.86
plasmenyl-PE 38:1; [M-H]-@8.13	ME189623	1.01	0.97	0.99	1.20	0.96
PE 42:9; [M-H]-@6.05	ME189573	0.98	0.99	1.04	1.13	0.93
PE 44:12; [M-H]-@5.65	ME189575	0.93	0.99	1.05	1.13	0.98
PI 36:2; [M-H]-@5.93	ME189595	0.91	0.97	1.05	1.20	1.00
PG 42:10; [M-H]-@4.63	ME189590	0.94	1.03	0.99	1.15	1.01
PS 42:6; [M-H]-@6.50	ME189612	0.93	1.00	0.99	1.21	1.03
PC 31:0; [M-Ac-H]-@6.20	ME189526	1.21	0.85	1.03	0.97	0.83
PC 33:1; [M-Ac-H]-@6.36	ME189530	1.27	0.82	0.98	1.07	0.83
PC 40:2; [M-Ac-H]-@7.96	ME189552	1.21	0.77	1.00	1.05	0.93
plasmenyl-PE 34:1; [M-H]-@7.07	ME189620	1.23	0.81	0.99	0.87	0.94
PC 35:1; [M-Ac-H]-@6.96	ME189535	1.14	0.78	1.10	0.90	0.91
PC 38:5; [M-Ac-H]-@6.33	ME189549	1.09	0.90	1.09	0.75	0.92
plasmenyl-PE 32:1; [M-H]-@6.51	ME189619	1.14	0.83	1.11	0.78	0.88
plasmenyl-PE 34:2; [M-H]-@6.64	ME189621	1.16	0.87	1.02	0.79	0.95
PC 36:0; [M-Ac-H]-@7.66	ME189536	1.13	0.86	1.08	0.88	0.88
PE 36:3; [M-H]-@6.46	ME189564	1.14	0.88	1.04	0.86	0.93
PS 38:6; [M-H]-@5.21	ME189605	1.14	0.73	1.03	0.95	1.05
FFA(24:1)	ME189520	1.10	0.74	1.06	1.03	1.02
PE 36:1; [M-H]-@7.34	ME189563	1.09	0.78	1.07	1.06	0.97
PE 41:6; [M-H]-@7.06	ME189570	1.01	0.93	0.95	0.98	1.15
PC 36:6; [M-Ac-H]-@5.40	ME189542	1.01	0.85	1.04	1.02	1.06
PC 38:2; [M-Ac-H]-@7.31	ME189546	1.02	0.88	1.02	1.14	1.02
PE 40:10; [M-H]-@5.07	ME189568	1.02	0.86	0.99	1.13	1.10
PG 44:12; [M-H]-@4.48	ME189594	1.03	0.89	0.98	1.07	1.08
PC 44:12; [M-Ac-H]-@5.49	ME189558	0.93	1.04	1.05	1.03	0.95
PG 44:11; [M-H]-@4.74	ME189593	0.94	0.95	1.06	1.00	1.02
PG 38:5; [M-H]-@5.55	ME189585	1.00	0.98	1.04	0.91	0.98
PG 38:6; [M-H]-@5.35	ME189586	1.02	0.98	0.99	0.90	1.05
FFA(22:1)	ME189516	0.99	0.91	1.13	0.91	0.92
PC 40:7; [M-Ac-H]-@6.14	ME189555	0.99	0.99	1.09	0.93	0.90
FFA(20:4) Arachidonic acid	ME189514	1.08	0.86	1.01	1.11	0.99
PC 36:2; [M-Ac-H]-@6.73	ME189538	1.10	0.87	1.00	1.07	0.98
PC 36:4; [M-Ac-H]-@6.12	ME189540	1.06	0.93	1.03	1.08	0.91
PC 38:3; [M-Ac-H]-@7.00	ME189547	1.08	0.87	1.04	1.09	0.92
PS 36:2; [M-H]-@5.98	ME189600	1.04	0.90	1.10	1.03	0.86
PS 34:1; [M-H]-@5.98	ME189598	1.03	0.85	1.11	1.09	0.89
PC 32:1; [M-Ac-H]-@5.99	ME189528	1.03	0.89	1.09	1.05	0.91
PS 40:6; [M-H]-@5.89	ME189607	1.03	0.87	1.10	1.06	0.92
PC 37:6; [M-Ac-H]-@5.74	ME189544	1.02	0.92	1.10	1.11	0.85
PS 38:4; [M-H]-@5.94	ME189603	1.04	0.87	1.09	1.17	0.87
PC 30:0; [M-Ac-H]-@5.85	ME189525	1.10	0.89	1.09	0.95	0.85
PC 36:1; [M-Ac-H]-@7.16	ME189537	1.12	0.93	1.06	0.90	0.84
FFA(22:0)	ME189515	1.11	0.89	1.05	0.98	0.89
PC 38:1; [M-Ac-H]-@7.73	ME189545	1.11	0.84	1.07	0.97	0.92
PC 34:2; [M-Ac-H]-@6.14	ME189533	1.06	0.86	1.10	0.97	0.90
PC 32:0; [M-Ac-H]-@6.46	ME189527	1.06	0.91	1.06	0.94	0.93
PE 42:10; [M-H]-@5.77	ME189571	1.06	0.92	1.06	0.98	0.91
PG 40:6; [M-H]-@5.98	ME189587	1.05	0.92	1.06	1.03	0.91
FFA(20:0)	ME189511	1.08	0.88	1.06	1.01	0.91
PG 34:1; [M-H]-@5.81	ME189578	1.06	0.89	1.08	1.00	0.91
PC 42:7; [M-Ac-H]-@6.75	ME189557	1.16	0.89	1.01	0.92	0.90
FFA(16:0)	ME189507	1.17	0.93	0.98	0.94	0.90
FFA(18:0)	ME189508	1.16	0.95	0.98	0.94	0.89
PS 36:4; [M-H]-@5.31	ME189601	1.18	1.00	0.99	1.00	0.77
PC 36:3; [M-Ac-H]-@6.37	ME189539	1.11	1.00	1.03	0.92	0.83
PC 34:1; [M-Ac-H]-@6.57	ME189532	1.12	0.94	1.03	0.98	0.84
PG 36:2; [M-H]-@5.94	ME189580	1.13	0.95	1.04	0.97	0.82
PC 38:4; [M-Ac-H]-@6.68	ME189548	1.13	0.98	0.98	1.02	0.87
PG 38:4; [M-H]-@6.02	ME189584	1.11	0.97	1.02	1.02	0.84
CL 70:3; [M-2H](2-)@9.57	ME189502	1.04	1.09	0.88	1.01	1.04
PC 39:6; [M-Ac-H]-@6.35	ME189551	1.16	1.00	0.91	1.04	0.92
PE 38:3; [M-H]-@7.23	ME189567	1.12	1.06	0.92	0.97	0.92
FFA(20:1)	ME189512	1.16	1.01	0.94	0.96	0.90
PE 32:0; [M-H]-@6.67	ME189559	1.15	1.06	0.93	0.94	0.86
plasmenyl-PE 36:3; [M-H]-@6.89	ME189622	1.08	1.04	0.98	1.03	0.87
PS 38:3; [M-H]-@6.19	ME189602	1.09	1.05	0.95	1.07	0.89
PC 40:6; [M-Ac-H]-@6.60	ME189554	1.06	0.99	0.98	1.06	0.94
PE 36:0; [M-H]-@7.77	ME189562	1.08	0.99	0.99	1.07	0.89
plasmenyl-PE 38:3; [M-H]-@7.52	ME189625	1.11	0.98	0.96	1.07	0.92
plasmenyl-PE 42:5; [M-H]-@7.79	ME189626	1.09	0.93	0.98	1.02	0.98
PE 44:10; [M-H]-@6.29	ME189574	1.08	1.03	0.95	1.02	0.95
PE 38:1; [M-H]-@7.83	ME189566	1.08	1.01	0.92	1.01	1.02
PS 40:4; [M-H]-@6.46	ME189606	1.07	1.01	0.93	1.02	1.00
PC 36:5; [M-Ac-H]-@5.60	ME189541	0.72	0.75	1.15	1.24	1.29
PC 28:0; [M-Ac-H]-@5.17	ME189524	1.05	0.75	1.07	1.33	0.96
PG 36:5; [M-H]-@5.05	ME189583	0.82	0.91	1.19	1.51	0.85

Factors:

F1	CRE:LysM Cre \| SEX:f
F2	CRE:negative \| SEX:f
F3	CRE:negative \| SEX:m
F4	CRE:Tyrosinase Cre \| SEX:f
F5	CRE:Tyrosinase Cre \| SEX:m

Data matrix